Many drugs may be potentially useful in the treatment of chronic obstructive pulmonary disease (COPD), but relatively few become available for human use due to lack of safety, lack of efficacy, or both. This is an inherent risk in the drug development process, which coupled with the limited understanding of the molecular pathogenesis of COPD, has produced a trend toward improving existing compounds rather than to develop new compounds. This review focuses on improved existing compounds and newly discovered compounds that are in clinical trials, but not yet marketed. The improved existing compounds include: isomers of the long-acting bronchodilators, once-daily b2-adrenoceptor agonists, anticholinergics and corticosteroids. The pool of novel compounds is in constant fluctuation and comprises anti-inflammatory drugs, antioxidants, leukotriene modifiers and a number of compounds aimed at treating different aspects of COPD such as pulmonary hypertension and hypophosphatemia.

Keywords:
Therapy, Chronic bronchitis, Emphysema, Drugs, Asthma, Treatments, Bronchodilators, Antimuscarinic, Anti-inflammatories
1.
National Institutes of Health, National Heart Lung and Blood Institute: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop, 2003.
2.
Giembycz MA: Development status of second generation PDE4 inhibitors for asthma and COPD: The story so far. Monaldi Arch Chest Dis 2002;57:48–46.
3.
Dallari R, Barozzi G, Pinelli G, et al: Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Respiration 1994;61:8–13.
4.
He Y, Taihing L, Shi Q, et al: A prospective study on smoking, quitting and mortality in a cohort of elderly in Xi’an, China. Zhonghua Liu Xing Bing Xue Za Zhi 2002;23:186–189.
5.
Strom K, Boe J: Quality assessment and predictors of survival in long-term domiciliary oxygen therapy. The Swedish Society of Chest Medicine. Eur Respir J 1991;4:50–58.
6.
Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ: Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax 2003;58:937–941.
7.
Barnes PJ: Chronic obstructive pulmonary disease. 12. New treatments for COPD. Thorax 2003;58:803–808.
8.
Dougherty JA, Didur BL, Aboussouan LS: Long-acting inhaled beta 2-agonists for stable COPD. Ann Pharmacother 2003;37:1247–1255.
9.
Friedman M, Della CG, Kottakis J: Formoterol therapy for chronic obstructive pulmonary disease: A review of the literature. Pharmacotherapy 2002;22:1129–1139.
10.
Zhang M, Fawcett JP, Shaw JP: Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. Br J Clin Pharmacol 2002;54:246–250.
11.
Zhang XY, Zhu FX, Olszewski MA, Robinson NE: Effects of enantiomers of beta-2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998;274:L32–L38.
12.
Zhang XY, Robinson NE, Zhu FX: Modulation of ACh release from airway cholinergic nerves in horses with recurrent airway obstruction. Am J Physiol 1999;276:L769–L775.
13.
Arformoterol: (R,R)-Eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D 2004;5:25–27.
14.
Waldeck B: Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists. Gen Pharmacol 1996;27:575–580.
15.
Weersink EJ, Postma DS, Koeter GH, Man Y, Nials AT, Coleman RA: Picumeterol: Dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics. Br J Clin Pharmacol 1997;43:169–176.
16.
Panning CA, DeBisschop M: Tiotropium: An inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003;23:183–189.
17.
Hansel TT, Barnes PJ: Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc) 2002;38:585–600.
18.
Schelfhout VJ, Joos GF, Ferrer P, Luria X, Pauwels RA: Activity of LAS 34273, a new long acting anticholinergic antagonist. Am J Respir Crit Care Med 2003;167:A93.
19.
Schelfhout VJ, Joos GF, Ferrer P, Kannies F, Luria X, Richter K, Pauwels RA: Activity of LAS34273, a new long acting anticholinergic antagonist, in COPD patients. Am J Respir Crit Care Med 2003;167:A319.
20.
Alabaster VA: Discovery and development of selective M3 antagonists for clinical use. Life Sci 1997;60:1053–1060.
21.
Turato G, Zuin R, Miniati M, et al: Airway inflammation in severe chronic obstructive pulmonary disease: Relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105–110.
22.
Saetta M, Mariani M, Panina-Bordignon P, et al: Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1404–1409.
23.
Maestrelli P, Saetta M, Mapp CE, Fabbri LM: Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:S76–S80.
24.
Jeffery PK: Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000;117:251S–260S.
25.
Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS: Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000;15:109–115.
26.
Rutgers SR, Postma DS, ten Hacken NH, et al: Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12–18.
27.
Finkelstein R, Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG: Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995;152:267–276.
28.
Linden M, Rasmussen JB, Piitulainen E, et al: Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993;148:1226–1232.
29.
Highland KB, Strange C, Heffner JE: Long-term effects of Inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003;138:969–973.
30.
Szafranski W, Cukier A, Ramirez A, et al: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74–81.
31.
Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912–919.
32.
Dent G: Ciclesonide (Byk Gulden). Curr Opin Investig Drugs 2002;3:78–83.
33.
Rohatagi S, Arya V, Zech K, et al: Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003;43:365–378.
34.
Molfino NA: Genetics of COPD. Chest 2004;125:1929–1940.
35.
Bonn D: Gene-directed cancer therapy starts to find its way. Lancet 1999;354:1364.
36.
FDA Pulmonary and Allergy Drugs Advisory Committee: Transcripts of the cilomilast (Ariflo) FDA Advisory Committee meeting. 2003.
37.
Tashkin DP, Cooper CB: The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125:249–259.
38.
Baumer W, Gorr G, Hoppmann J, Ehinger AM, Rundfeldt C, Kietzmann M: AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol 2003;55:1107–1114.
39.
Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C: In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003;307:373–385.
40.
Baumer W, Gorr G, Hoppmann J, Ehinger AM, Ehinger B, Kietzmann M: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis. Eur J Pharmacol 2002;446:195–200.
41.
Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM: Inhibition of the TNF-pathway: Use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002;132:414–422.
42.
Holtmann MM: RDP-58 (SangStat Medical). IDrugs 2003;6:1188–1194.
43.
Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R: Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther 2002;301:241–248.
44.
Romano SJ, Slee DH: Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs 2001;2:907–913.
45.
Chung KF: Current and future prospects for drugs to suppress cough. IDrugs 2003;6:781–786.
46.
Joos GF, Pauwels RA: Tachykinin receptor antagonists: Potential in airways diseases. Curr Opin Pharmacol 2001;1:235–241.
47.
Rahman I: Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J Biochem Mol Biol 2003;36:95–109.
48.
Rahman I, van Schadewijk AAM, Crowther AJL, et al: 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:490–495.
49.
Kasielski M, Nowak D: Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001;95:448–456.
50.
Van Overveld FJ, Vermeire PA, De Backer WA: Induced sputum of patients with chronic obstructive pulmonary disease (COPD) contains adhesion-promoting, therapy-sensitive factors. Inflamm Res 2000;49:8–13.
51.
Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM: N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999;66:495–500.
52.
Maestrelli P, Paska C, Saetta M, et al: Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 2003;21:971–976.
53.
Rutgers SR, van der Mark TW, Coers W, et al: Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999;54:576–580.
54.
Van Straaten JF, Postma DS, Coers W, Noordhoek JA, Kauffman HF, Timens W: Macrophages in lung tissue from patients with pulmonary emphysema express both inducible and endothelial nitric oxide synthase. Mod Pathol 1998;11:648–655.
55.
Hansel TT, Kharitonov SA, Donnelly LE, et al: A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003;17:1298–1300.
56.
Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM: In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther 2001;297:458–466.
57.
Gronke L, Beeh KM: LTB 019 A, a leukotriene B(4) receptor antagonist, has no effect on the levels of neutrophils, MPO, IL-8 and TNF-alpha in induced sputum of patients with COPD. Am J Respir Crit Care Med 2002;165:A598.
58.
Donnelly LE, Rogers DF: Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003;63:1973–1998.
59.
Wark PA: DX-890 (Dyax). IDrugs 2002;5:586–589.
60.
Luisetti M, Sturani C, Sella D, et al: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996;9:1482–1486.
61.
Massaro GD, Massaro D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3:675–677.
62.
Aoki K: [Retinoic acid and regeneration therapy of the lung diseases]. Nippon Rinsho 2003;61:2220–2222.
63.
Fujita M, Ye Q, Ouchi H, et al: Retinoic acid fails to reverse emphysema in adult mouse models. Thorax 2004;59:224–230.
64.
Sofia M, Mormile M, Faraone S, et al: Increased 24-hour endothelin-1 urinary excretion in patients with chronic obstructive pulmonary disease. Respiration 1994;61:263–268.
65.
Spiropoulos K, Trakada G, Nikolaou E, et al: Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma. Respir Med 2003;97:983–989.
66.
Trakada G, Marangos M, Spiropoulos K: Mechanisms of endothelin-1 elevation in chronic obstructive pulmonary disease patients with nocturnal oxyhemoglobin desaturation. Respiration 2001;68:134–139.
67.
Coe Y, Haleen SJ, Welch KM, Liu YA, Coceani F: The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb. J Pharmacol Exp Ther 2002;302:672–680.
68.
Coe Y, Haleen SJ, Welch KM, Coceani F: The endothelin-A-receptor antagonist PD 180988 (CI-1034) selectively reverses the pulmonary vasoconstrictor response to hypoxia in the lamb. J Cardiovasc Pharmacol 2000;36:S331–S333.
69.
Fiaccadori E, Coffrini E, Fracchia C, Rampulla C, Montagna T, Borghetti A: Hypophosphatemia and phosphorus depletion in respiratory and peripheral muscles of patients with respiratory failure due to COPD. Chest 1994;105:1392–1398.
70.
Fiaccadori E, Coffrini E, Ronda N, et al: Hypophosphatemia in course of chronic obstructive pulmonary disease. Prevalence, mechanisms, and relationships with skeletal muscle phosphorus content. Chest 1990;97:857–868.
71.
Marchesani F, Valerio G, Dardes N, Viglianti B, Sanguinetti CM: Effect of intravenous fructose 1,6-diphosphate administration in malnourished chronic obstructive pulmonary disease patients with chronic respiratory failure. Respiration 2000;67:177–182.
72.
Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R: Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. J Biol Chem 1999;274:19965–19972.
73.
Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG: Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999;66:401–410.
74.
White JR, Lee JM, Young PR, et al: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095–10098.
75.
De Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS: Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000;190:619–626.
76.
Fedorak RN, Gangl A, Elson CO, et al: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473–1482.
77.
Barnes PJ: Future advances in CODP therapy. Respiration 2001;68:441–448.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.